Our results with combined G-CSF administration and Bcl-xL blockade suggest a qualitative change of the tumor-infiltrating neutrophil pool, whereby old, tumor-supportive TANs are replaced by younger, possibly tumor-antagonizing neutrophils. The gene discussed is BCL2L1; the disease is neoplasm.